news
Daiichi Sankyo’s edoxaban launched in the UK
10 July 2015 | By Victoria White
Edoxaban, a new blood-thinning drug therapy to help prevent stroke in patients with non-valvular atrial fibrillation, has been launched in the UK...
List view / Grid view
Stroke
news
Stroke rates have dramatically increased over the past 15 years
12 May 2015 | By Victoria White
The number of strokes occurring in men aged between 40 and 54 has rocketed by almost 50% in less than 15 years, according to the Stroke Association...
news
ReNeuron provides more data from Phase I trial of CTX stem cell therapy for stroke patients
21 April 2015 | By Victoria White
ReNeuron has provided a further and final update on the PISCES Phase I clinical trial of its CTX stem cell therapy for disabled stroke patients...
news
Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
news
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk
9 January 2015 | By Daiichi Sankyo
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...
news
Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
news
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
8 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference, Nice, France...
news
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
7 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference...
news
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
6 March 2014 | By Boehringer Ingelheim
More than 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition...
news
Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
news
Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
news
New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years
19 November 2013 | By Boehringer Ingelheim
Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention...
news
ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations
26 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...
news
New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF
17 June 2013 | By Boehringer Ingelheim
New long-term data from the RELY-ABLE® study...
news
RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa®
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
